The purpose of the Cancer Genomics Shared Resource (CGSR) is to maximize scientific and clinical impact of Atrium Health enterprise-wide research toward the discovery and characterization of genomic, transcriptomic and epigenetic alterations that:
- underlie cancer formation and progression,
- explain inter- and intra-tumoral molecular and clonal heterogeneity,
- predict clinical cancer behavior and treatment outcomes, and
- impact tumor-immune and drug-response interactions.
The CGSR achieves this mission by providing rapid and cost-effective access to state-of-the-art Next Generation DNA sequencing (NGS) technologies, expertise in clinical assay development, and interdisciplinary collaboration and education in the genomic sciences.
The CGSR prioritizes cancer-specific research, creates an optimal environment for the Institution’s rapidly developing Precision Oncology Initiative (POI), and partners with other key Shared Resources (SRs) to promote integrated cross-SR service workflows for advanced genomic applications such as single-cell and spatial single-cell expression profiling.
The Molecular Biology and Genomics Core Laboratory, which recently merged with the CGSR, is a full-service, CLIA certified facility located in the Levine Cancer Institute at Carolinas Medical Center under the direction of Nury Steuerwald, PhD, HCLD (ABB). Its mission is to develop and offer novel clinical molecular diagnostic tests in support of our clinicians and for the benefit of our patients.
- Whole genome/whole exome sequencing
- RNA sequencing
- Single cell RNA sequencing and multi-omic/spatial analysis
- Nucleic acid (RNA/DNA) isolation and QC
- Development of clinical genomic tests
2. Triozzi PL, Stirling ER, Song Q, Westwood B, Kooshki M, Forbes ME, et al. Circulating Immune Bioenergetic, Metabolic, and Genetic Signatures Predict Melanoma Patients' Response to Anti-PD-1 Immune Checkpoint Blockade. Clin Cancer Res 2022;28:1192-202
3. Lu Y, Xue G, Zheng N, Han K, Yang W, Wang RS, et al. hDirect-MAP: projection-free single-cell modeling of response to checkpoint immunotherapy. Brief Bioinform 2022;23
4. Liu Y, Wang L, Song Q, Ali M, Crowe WN, Kucera GL, et al. Intrapleural nano-immunotherapy promotes innate and adaptive immune responses to enhance anti-PD-L1 therapy for malignant pleural effusion. Nat Nanotechnol 2022;17:206-16
5. Crouse WL, Das SK, Le T, Keele G, Holl K, Seshie O, et al. Transcriptome-wide analyses of adipose tissue in outbred rats reveal genetic regulatory mechanisms relevant for human obesity. Physiol Genomics 2022;54:206-19
6. Burgess EF, Sanders JA, Livasy C, Symanowski J, Gatalica Z, Steuerwald NM, et al. Identification of potential biomarkers and novel therapeutic targets through genomic analysis of small cell bladder carcinoma and associated clinical outcomes. Urol Oncol 2022;40:383 e1- e10
7. Sanders JA, Frasier C, Matulay JT, Steuerwald NM, Zhu J, Grigg CM, et al. Genomic analysis of response to bacillus Calmette-Guerin (BCG) treatment in high-grade stage 1 bladder cancer patients. Transl Androl Urol 2021;10:2998-3009
8. Patel JN, Voora D, Bell G, Bates J, Cipriani A, Bendz L, et al. North Carolina's multi-institutional pharmacogenomics efforts with the North Carolina Precision Health Collaborative. Pharmacogenomics 2021;22:73-80
9. Patel JN, Arnall J, Jandrisevits E, Morse AL, Steuerwald N, Copelan E, et al. Pharmacogenomics-guided supportive oncology: A tale of two trials. Contemp Clin Trials 2021;105:106391
10. Norris EJ, Patel YC, Klotz KE, Steuerwald N, Jones WD, Maciejewski JP, et al. Dexrazoxane enhances efficacy of all-trans retinoic acid in acute myeloid leukemia patient blast cells and cell lines. Leuk Lymphoma 2021;62:473-7
11. Livingston MB, Jagosky MH, Robinson MM, Ahrens WA, Benbow JH, Farhangfar CJ, et al. Phase II Study of Pembrolizumab in Combination with Doxorubicin in Metastatic and Unresectable Soft-Tissue Sarcoma. Clin Cancer Res 2021;27:6424-31
12. Su J, Song Q, Qasem S, O'Neill S, Lee J, Furdui CM, et al. Multi-Omics Analysis of Brain Metastasis Outcomes Following Craniotomy. Front Oncol 2020;10:615472
13. Price A, Druhan LJ, Lance A, Clark G, Vestal CG, Zhang Q, et al. T618I CSF3R mutations in chronic neutrophilic leukemia induce oncogenic signals through aberrant trafficking and constitutive phosphorylation of the O-glycosylated receptor form. Biochem Biophys Res Commun 2020;523:208-13
14. Patel JN, Hamadeh IS, Robinson M, Shahid Z, Symanowski J, Steuerwald N, et al. Evaluation of CYP2C19 Genotype-Guided Voriconazole Prophylaxis After Allogeneic Hematopoietic Cell Transplant. Clin Pharmacol Ther 2020;107:571-9
15. Foureau DM, Bhutani M, Robinson M, Guo F, Pham D, Buelow B, et al. Ex vivo efficacy of BCMA-bispecific antibody TNB-383B in relapsed/refractory multiple myeloma. EJHaem 2020;1:113-21
16. Druhan LJ, Lance A, Hamilton A, Steuerwald NM, Tjaden E, Avalos BR. Altered splicing and intronic polyadenylation of CSF3R via a cryptic exon in acute myeloid leukemia. Leuk Res 2020;92:106349